Langerhans cell sarcoma – European Clinical Trials Information Network

Study on the Use of Fludeoxyglucose (18F) in PET/CT Scans for Young Patients with Histiocytosis

Wed, 29 Apr 2026 15:00:12 +0000

This clinical trial focuses on a condition known as histiocytosis, which involves the excessive growth of certain immune cells called histiocytes. The study aims to explore the use of a special imaging technique called PET/CT to better understand the disease in young patients. The imaging process uses a substance called Fludeoxyglucose (18F), which is a type of sugar that helps highlight areas of the body during scans. This trial will help determine the benefits and safety of using this imaging method in children and teenagers with histiocytosis.

Participants in the study will undergo PET/CT imaging to assess the molecular profile of their condition. If a specific mutation is detected, it will be monitored over time. The study will evaluate how well the imaging technique works in providing useful information about the disease and its progression. The trial will also look at how the disease responds to treatment and monitor any side effects that may occur.

The goal of the study is to improve understanding of histiocytosis and to see if using Fludeoxyglucose (18F) in PET/CT imaging can provide valuable insights into the disease. This research could potentially lead to better ways to monitor and manage histiocytosis in young patients, helping to improve their overall care and outcomes.

Study on Vemurafenib for Children with BRAF Mutation-Resistant Histiocytosis

Wed, 29 Apr 2026 15:00:11 +0000

This clinical trial is focused on studying a condition known as histiocytic cell proliferation, which involves an abnormal increase in certain immune cells. The trial is specifically looking at cases where this condition is resistant to standard treatments. The study will use a medication called vemurafenib, which is taken as a film-coated tablet. Vemurafenib is designed to target a specific genetic change, known as the BRAF mutation, that can occur in these cells.

The purpose of the study is to evaluate the safety, effectiveness, and tolerability of vemurafenib in children who have this BRAF mutation and whose condition has not responded to other treatments. Participants will receive vemurafenib and will be monitored to determine the best dosage and duration of treatment. The study will also assess how well the drug works in preventing the disease from getting worse and how long patients can live without the disease progressing.

Throughout the study, various health checks will be conducted, including monitoring vital signs, performing laboratory tests, and using imaging techniques like MRI to ensure the safety of the participants. The trial aims to find a dose for children that provides similar benefits as those seen in adults. The study will also look at how often the disease comes back after two years of treatment. Participants will be closely observed for any side effects or adverse events during the trial.

Study on Trametinib Dimethyl Sulfoxide for Children with Refractory Histiocytosis Not Responding to Conventional Treatment

Wed, 29 Apr 2026 15:00:11 +0000

This clinical trial is focused on studying a condition known as histiocytic cell proliferation, which involves an abnormal increase in certain immune cells. The trial is testing a medication called Trametinib Dimethyl Sulfoxide, which is taken as a film-coated tablet. The purpose of the study is to evaluate the safety, effectiveness, and how well patients tolerate this drug, as well as to determine the best duration of treatment for children whose condition has not improved with standard therapies.

Participants in the study will receive the medication Trametinib to see if it can help manage their condition, especially if they have not responded to other treatments like Vemurafenib. The study will also include a comparison with a placebo to better understand the drug’s effects. The trial will monitor participants over a period to assess their response to the treatment and any side effects they may experience.

The study aims to find the right dose of Trametinib for children under 18, ensuring it is similar to the dose recommended for adults. Throughout the trial, various health checks, including laboratory tests and heart monitoring, will be conducted to ensure the safety of the participants. The trial will also look at how long patients can live without the disease getting worse and the overall survival rate. The study is expected to continue until March 2026.